logo
Share SHARE
FONT-SIZE Plus   Neg

New Data On Novartis' Lucentis Confirms Benefits Of Individualized Treatment

Novartis AG (NVS) said new data for Lucentis (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections.

In addition, Lucentis exhibited benefits in visual acuity outcomes in patients with visual impairment due to choroidal neovascularization secondary to pathological myopia. At present, Lucentis is not approved to treat this condition. Novartis noted that it will submit for regulatory approval in this indication in the European Union in the third quarter of this year and in Japan by late 2012.

Tim Wright, Global Head of Development, Novartis Pharma, commented, "Lucentis has become the standard of care in wet AMD and has helped to significantly improve vision in a majority of patients with this disease. These new data confirm that an individualized treatment approach can lead to optimal improvements in vision with a low average number of treatments, thus ensuring that patients with retinal diseases are not over- or under-treated. In addition, these data add to the well-characterized safety profile of Lucentis."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A blast at the Al-Imam al-Sadeq mosque in Kuwaiti capital killed eight people. Several people were wounded in the explosion, probably a suicide bombing, after the Friday prayers. Many are said to be in critical condition. One was killed in a probable ISIS attack at U.S. based Air products and Chemicals' industrial site in France. According to media reports, a car disguised as a delivery vehicle was rammed into Air product site in Schiltigheim, Southeast France. Police arrested a young man of around 30 years old, who is suspected to have connections with Islamic State. Nike Inc., the world's largest athletic shoes and apparel maker, said Thursday after the markets closed that its fourth quarter profit rose 24% from last year, helped by higher revenue and improved gross margin amid strong growth in North America.
comments powered by Disqus
Follow RTT